Literature DB >> 3107849

5-fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy in advanced adenocarcinoma of the lung: comparison of two dosage schedules.

W K Lam, S Y So, T M Kung, M K Sham, M Ip.   

Abstract

Fifty patients with inoperable adenocarcinoma of the lung were randomized in a prospective study to receive either standard doses or high doses of 5-fluorouracil, adriamycin, and mitomycin-C (FAM versus Hi-FAM). The response/stabilization rate was 32% for FAM and 34% for Hi-FAM (P greater than 0.05), and the median survival was 27 weeks for FAM group and 24 weeks for Hi-FAM group (P greater than 0.05). Myelotoxicity was mild in FAM, but moderate to severe in Hi-FAM. It is concluded that Hi-FAM did not yield a higher response rate or median survival compared with FAM, but caused significantly more severe myelotoxicity.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3107849     DOI： 10.1007/bf00252986

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  14 in total

1.  Alkylating agents in bronchogenic carcinoma.

Authors:  R A Green; E Humphrey; H Close; M E Patno
Journal:  Am J Med       Date:  1969-04       Impact factor: 4.965

Review 2.  Chemotherapy of lung cancer.

Authors:  S K Carter
Journal:  Semin Oncol       Date:  1982-12       Impact factor: 4.929

Review 3.  Chemotherapy of metastatic non-small cell bronchogenic carcinoma.

Authors:  P C Hoffman; J D Bitran; H M Golomb
Journal:  Semin Oncol       Date:  1983-03       Impact factor: 4.929

4.  Commentary: current status of chemotherapy for non-small cell lung cancer.

Authors:  J Aisner; H H Hansen
Journal:  Cancer Treat Rep       Date:  1981 Nov-Dec

5.  Adenocarcinoma of the lung: recent results from the Veterans Administration Lung Group.

Authors:  J D Cox; R A Yesner
Journal:  Am Rev Respir Dis       Date:  1979-11

6.  Failure of intensive combination therapy (cyclophosphamide, adriamycin, 5-fluorouracil) to control adenocarcinoma or large-cell anaplastic carcinoma of lung.

Authors:  R E Taylor; I E Smith; H T Ford; B M Bryant; A J Casey; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

7.  The changing histopathology of lung cancer: a review of 1682 cases.

Authors:  R G Vincent; J W Pickren; W W Lane; I Bross; H Takita; L Houten; A C Gutierrez; T Rzepka
Journal:  Cancer       Date:  1977-04       Impact factor: 6.860

8.  5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for adenocarcinoma of the lung.

Authors:  T P Butler; J S MacDonald; F P Smith; L F Smith; P V Woolley; P S Schein
Journal:  Cancer       Date:  1979-04       Impact factor: 6.860

9.  5-fluorouracil, adriamycin, and mitomycin-C (Hi-FAM) chemotherapy for adenocarcinoma of the lung.

Authors:  D R Rosi; C Nogeire; B Brown; M Ali; M Ewer; M Samuels
Journal:  Cancer       Date:  1981-07-01       Impact factor: 6.860

10.  Lung cancer in Hong Kong Chinese: mortality and histological types, 1973-1982.

Authors:  I T Kung; K F So; T H Lam
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.